E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Epilepsy with partial seizures (including secondarily generalized seizures) |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic disorder of brain function characterized by seizures |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and efficacy of gabapentin in the 52 weeks as add-on therapy in the treatment of pediatric subjects with partial seizures (including secondarily generalized) when other antiepileptics do not provide satisfactory effects. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subjects must complete 12 week treatment on A9451162 study.
2. Subjects Females of childbearing potential have a negative urine pregnancy test at screening.
3. Subjects and legal guardians must be thought to be compliant and able to follow the investigator’s instructions. They must be able to visit the clinic on schedule, be co-operative and reliable. They, or reliable observers, must be thought able to document the occurrence of seizures.
4. Subjects and /or legal guardians must give written informed consent prior to the start of the study. The acquisition of informed consent is made by subjects as much as possible.
|
|
E.4 | Principal exclusion criteria |
1. Subjects with seizures related to drugs, or acute medical illness.
2.Any subject at screening with an Aspartate transferase (AST),Alanine transaminase (ALT), total bilirubin, Blood urea nitrogen (BUN) or creatinine above twice the upper limit of normal range at screening (Visit6 of study A9451162).
3. Any subject at screening with a white blood cell counts below 3000/milliliter (mm)^3 or neutrophil counts below 1500/mm^3 at screening (Visit6 of study A9451162).
4. Subjects with a history of any serious medical or psychiatric disorder within the previous 6 months.
5. Subjects taking any non-antiepileptic drug (AED) medication that could alter the effectiveness of the subject’s medication response, seizure frequency or characteristics.
6. Any subject not reasonably expected to complete the trial.
7. Subjects who withdrew from the treatment period of A9451162.
8. Subjects with any other condition in which the investigator judge the subject unsuitable for participation in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Number of Subjects With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) up to 53 weeks |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Response Ratio Up to 52 weeks
Responder Rate Up to 52 weeks
Percent Change in Seizure Frequency Up to 52 weeks |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 25 |